In the course of scientific discovery, there are triumphant moments when researchers present their findings to a rapt audience that jumps to its feet for a standing ovation. It happened in a conference room full of doctors in May after they learned a new drug, daraxonrasib, nearly doubled survival time for pancreatic cancer patients.
A promising drug for an inherited heart risk flops, stunning doctors | CNN

Results are in for a highly anticipated study of an experimental drug meant to reduce major heart events by lowering lipoprotein (a). To the surprise of doctors, the drug didn’t work.
Too much lipoprotein (a) is thought to promote clotting in the arteries around the heart as well as raising inflammation. There's no specific treatment for high Lp(a).
brizmaker/iStockphoto/Getty Images
See all topics
Email
Link Copied!



